Bluejay Diagnostics and Lovell Government Services Announce Partnership to Expand Access to U.S. Federal Healthcare Markets
Bluejay Diagnostics (NASDAQ: BJDX) signed a distribution, co-marketing and strategic partnership with Lovell Government Services, which becomes Bluejay's exclusive distributor for federal procurement opportunities requiring or favoring SDVOSB status across the VA, DoD, Military Health Systems and Indian Health Service. The arrangement is contingent on regulatory approval — the Symphony sepsis-triage platform remains investigational, and the SYMON-II pivotal study is intended to support a 510(k) application to the FDA.
Key figures
- Regulatory status
- investigational, no FDA clearance; SYMON-II pivotal study to support 510(k)
- Military hospitals
- 45
- Ihs patients served
- 2.8 million
- Vha medical centers
- 170
- Vha outpatient clinics
- 1193
- Symphony time to result
- approximately 20 minutes
- Amsus professional reach
- 8,000+
- Military medical clinics
- 572
- Dha proposed fy2026 budget
- $64 billion
- Ihs proposed fy2026 budget
- $8.1 billion
- Vha proposed fy2026 budget
- $165.1 billion
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.